Gustavo Viani, Professor at the Faculty of Medicine of Botucatu, São Paulo State University (UNESP), shared a post on LinkedIn:
“PORTEC-3: Changing the Standard in High-Risk Endometrial Cancer
The gap
Until PORTEC-3, we lacked long-term evidence on whether chemoRT > RT alone in high-risk EC.
Results (10-year follow-up)
- OS: 74.4% vs 67.3% (HR 0.73)
- RFS: 72.8% vs 67.4%
- Clear benefit in p53-abn and stage III
- No added value for POLEmut or MMRd
Impact
- Molecular profiling + staging = the new way forward.
- ChemoRT is now standard for p53-abn and advanced stage patients.
Take-home
- Not all high-risk EC are equal to precision adjuvant therapy is essential.
See more.”
More posts featuring Gustavo Viani